Search   |   Print Page   |   Contact Us   |   Sign In   |   Join
Community Search
Advances in Brain Stimulation
View Registrations Tell a Friend About This EventTell a Friend

Advances in Brain Stimulation - understanding and treating debilitating brain diseases

When: Feb 6, 2019
5:30-8:30 PM
Where: Regis College, Fine Arts Center
235 Wellesley St
Weston, Massachusetts  02493
United States
Contact: Bill Munger

Online registration is closed.
« Go to Upcoming Event List  

Wed Feb 6 - MDG Boston FORUM
Advances in Brain Stimulation

Technological advances in imaging,
in detection of brain electrical activity
and in data analytics are creating
new understanding of the brain disorders.
Our speakers will discuss both
the technology and implications
of these breakthroughs for understanding
and treating debilitating brain diseases.
Program Description  

Recent breakthroughs in data analytics and AI are allowing new insights and treatments for the common brain disorders of mood, cognitive function and movement.  This progress results from researching previously inaccessible information contained in EEG and Magnetic Field signals which accompany the brain's electrical activity.
Applied electric fields have been shown to alleviate depression, as in electric shock treatment, while application of Low Field Magnetic Stimulation (LFMS) is a promising electromagnetic treatment that addresses a range of mood and anxiety related symptoms.
Mike Rohan, PhD, Lecturer on Psychiatry at Harvard Medical School and physicist at McLean Hospital Imaging Center, will describe the use of Low Field Magnetic Stimulation (LFMS). an electromagnetic treatment for depression that addresses a range of mood and anxiety related symptoms. It is a series of low strength, high frequency, electromagnetic field pulses that produces rapid improvements in mood.

Ana Maiques, CEO of Neuroelectrics, will discuss how non-invasive brain stimulation can become a new at-home therapy for patients suffering from epilepsy or Alzheimer's disease. She will describe how to develop new business models to enable these new developments to reach patients at home for help when drugs are not providing adequate relief.  

Dr. Ron Alterman, Chief of Neurosurgery at the Beth-Israel Deaconess Medical Center, will discuss use of electric stimulation applied via advanced stereotactic surgical methods to exact sites within the brain for treatment of movement and psychiatric disorders.

Jim Kirk has been asked to provide a patient's perspective on how the experience and symptoms of Parkinson's disease led to his decision to undergo DBS, and how his life has changed since then.

Our session is moderated by Dr. Teo Dagi, neurosurgeon, investor, consultant and esteemed academic and MDG Advisory Board Member.


Feb 6, 5:30 - 8:30 PM
Regis College Fine Arts Center
Weston, MA
MDG Boston Forum Fees
 Member/Alliance Partner - $45  
   Non-member - $65 
   Student (member) - $15
   Student (non-member) - $20
Gold Member - No Charge
Event Sponsor
  Event Sponsorship - $500  
 (contact Hank Allard for details 
We hope you can join us  
for this conversation 
Who Should Attend: 
  • Scientists and Engineers who are interested in how electric and magnetic fields can detect and alleviate thought, emotion and coordinated brain activity.
  • Caregivers interested in emerging concepts of how disease, thought and mood disorders can be better understood by data analytics for electromagnetic brain signals.
  • Managers and investors seeking opportunities in emerging CNS technology.
  • AI and data analytic professionals whose technology promises new insights into understanding brain function.
Our Distinguished Panel
Michael L Rohan, PhD
McLean Hospital Imaging Center - Physicist
Harvard Medical School - Lecturer in Psychiatry
Ana Maiques, MBA
Neuroelectrics, CEO
Ron L. Alterman, MD
Beth Israel Deaconess Medical Center, Chief, Division of Neurosurgery Harvard Medical School, Professor of Neurosurgery
James Kirk 
Patient of Dr. Alterman 
Boston Neurosciences, CEO

Panel Bios     
Michael L Rohan, PhD      
Physicist, McLean Hospital Imaging Center and Lecturer in Psychiatry, Harvard Medical School
After a career developing and producing the first fMRI systems at Advanced NMR Systems Inc. (1986-1999), Michael L. Rohan, came to McLean Hospital and Harvard Medical School. Here, as both a physicist and neuroscientist, he has developed Low Field Magnetic Stimulation (LFMS) from a hypothesis based on a clinical observation into a medical device that has been evaluated by the NIH as part of its RAPID program for fast acting antidepressants.

Low Field Magnetic Stimulation (LFMS) is an electromagnetic treatment for depression that addresses a range of mood and anxiety related symptoms. It is a series of low strength (1 V/m), high frequency (91 kHz) electromagnetic field pulses that produces rapid improvements in mood. The low electric field strength and high frequency pulses employed by LFMS are different from those used in other electromagnetic treatments, as is the rapid clinical response that LFMS provokes - subjects report mood improvement within minutes, rather than within weeks. These differences suggest that LFMS is exploiting a novel mechanism for its effects on symptoms of depression and anxiety. The effects of LFMS on mood have been primarily observed in subjects with bipolar depression, although studies including subjects with major depression have demonstrated a similar response.

Ana Maiques, MBA
CEO, Neuroelectrics
Ana Maiques is the CEO of Neuroelectrics, a company aiming to change the way we interact with the brain, developing innovative technologies to monitor and stimulate the brain to help many patients in need. She was nominated by IESE as one of the most influential entrepreneurs under 40 in Spain (2010) and received the EU Prize for Women Innovators from the European Commission EC in 2014 and one of the Most Inspiring Fifty Women in Europe. Neuroelectrics recently received the Best Start-up in Health 2015 bye Wired UK magazine in an amazing event in London. She now lives in Boston where Neuroelectrics was awarded as one of the 2016 Best Entrepreneurial Companies in USA by Entrepreneur Magazine.

Ana will describe new trends in digital therapeutics and how non-invasive brain stimulation can become a new at-home therapy for patients suffering from epilepsy or Alzheimer. She will describe how to develop new business models to make sure technologies reach patients' homes and help where drugs are not providing solutions to large populations in need. She will also provide a live demonstration of the Neuroelectrics device.

Ron L. Alterman, MD
Beth Israel Deaconess Medical Center, Chief, Division of Neurosurgery Harvard Medical School, Professor of Neurosurgery
Ron L. Alterman, M.D. is Professor of Neurosurgery at Harvard Medical School and Chief of the Division of Neurosurgery within the Roberta and Stephen R. Weiner Department of Surgery at Beth Israel Deaconess Medical Center (BIDMC). He specializes in Stereotactic Procedures for brain tumors, movement disorders, and psychiatric disorders

Dr. Alterman received his Bachelor of Arts magna cum laude from the University of Pennsylvania and his Medical Doctorate with distinction (AOA) from the Albert Einstein College of Medicine. He interned at Washington University in St. Louis, and completed his Neurosurgery Residency training at Montefiore Medical Center in New York and then joined the NYU Neurosurgery Faculty.

In 1998 he moved to New York's Beth Israel Medical Center where he established the busiest deep brain stimulation program in the New York Tri-State region. In 2002 he earned his M.B.A. with Honors from Columbia Business School. In 2003, he served at Walter Reed Army Hospital in Washington, DC in support of Operation Iraqi Freedom and was honorably discharged from the U.S. Army Reserve Medical Corps at the rank of lieutenant colonel in 2008.

Dr. Alterman became Chief of the Division of Neurosurgery at BIDMC in 2011. Under his leadership, BIDMC Neurosurgery has doubled its faculty and grown its clinical volume more than 50%. Centers of excellence have been established in Functional neurosurgery, Neuro-oncology, and Vascular/Endovascular Neurosurgery. Dr. Alterman has received numerous honors throughout his career, including the Young Neurosurgeon Award from the World Society for Stereotactic and Functional Neurosurgery.



Over the last quarter century, various forms of Neural Stimulation have dramatically impacted the treatment of many neurological disorders including chronic pain, Parkinson’s disease, tremor, dystonia, epilepsy, obsessive compulsive disorder and depression. While these successes underscore the potential of neural stimulation to restore and even enhance human function, the field of neuromodulation is still nascent, its full impact on the human experience not nearly realized.


I will provide an overview of the field of neural stimulation, focusing on Deep Brain Stimulation (DBS), the most successful of these technologies to date, as a model. I will demonstrate the potential of the technology, even in its current rudimentary form, and discuss the technological and neurobiological obstacles to making neural stimulation even more effective and therefore more widely employed. I will also touch on competing technologies for modulating neural function and the ethical challenges our field faces as we move these technologies forward.

James Kirk  
James, a patient of Dr. Alterman’s, will share the story of his benefits from Deep Brain Stimulation. Jim is an experienced teacher, presenter and consultant with extensive clinical and scientific background. He was VP of Quintiles, a world leader in clinical research, where he was responsible for strategy, budget, operations and personnel. He also co-founded a preeminent biopharma market research firm, and was a manager for both Ocean Spray and Gillette earlier in his career.  
James has a BA in Biochemistry from Harvard, and an MA from Stanford in Science Education and Cirriculum Development. He has had Parkinson’s for 17 years, and received Deep Brain stimulation (DBS) 4½ years ago. Currently Jim spends his timedoing volunteer work for various Parkinson’s teams, including coaching Rock Steady Boxing, and acting as a patient advocate for a team building a comprehensive DBS registry.
Jim has been asked to provide a patient’s perspective on how the experience and symptoms of Parkinson’s disease led to his decision to undergo DBS, and how his life has changed since then. Given his long history with Parkinson’s and with DBS, his comments will focus on the course of the disease, and how that has - and has not - been changed by DBS. Jim will recount the process of qualifying and preparing for the procedure, and the history since then of “powering up” the implants and re-tuning them as needed. He will also share his experiences working with Dr. Ron Alterman as a DBS Ambassador for the Beth Israel program

Teo is the CEO of Boston Neurosciences, Inc., a Boston-based, venture-backed clinical-stage company developing instruments for non-invasive intracranial pressure measurement. He is a neurosurgeon turned VC, whose portfolio includes numerous companies now on traded on the NASDAQ.  
Teo is Director of Life Sciences at Anglo Scientific of the Royal Institution of Great Britain and has served on many boards, including the Advisory Board of MDG. Teo has published over 150 articles and book chapters, has authored several books and was a Neuroresearch Foundation Fellow of the MGH, and has focused research on brain stimulation.


Peter Madras, MD
President MDG Boston
Lecturer, Sloan School
of Management, MIT
Alan Oslan, MBA
President & Founder ElectroSurge, LLC
Fees -  (Light dinner included)
Fee Category Early Registration
(By Jan 30)
Week Prior
(Jan 30 - Feb 6)

At the Door
(Feb 6
Member/Alliance Partner: $30 $35 $45
Non-Member: $45 $55 $65
Student Member $10 $12 $15    
Student Non-member w/ a valid ID $15 $18 $20 
Gold Member No Charge No Charge  No Charge 
Event Sponsor - $500 -  (contact Hank Allard for details -
About MDG
The premier MedTech community advancing healthcare  
by enabling diverse professionals to grow through  
expert forums, collaboration, and knowledge sharing.
The Medical Development Group (MDG) is a community of individuals professionally committed to the Medical Device and other Medical Technology Industry segments united by the belief that innovation and advances in technology lead to substantial improvements in health care. MDG pursues this mission through the organization of educational programs and forums: the facilitation of cross-disciplinary dialogue and collaboration; the creation of venues for networking and information sharing for current and aspiring professionals, clinicians, and entrepreneurs; and the development of alliances with complementary organizations.

more MDG Calendar

Human-Centered Medical Device Design for Global Health

MDG Boston Sponsors


 Medical Development  Group
 POB 555
 Concord, MA 01742







 About Us
 Terms of Use
 Privacy Policy








Association Management Software Powered by YourMembership  ::  Legal